Concomitant use of dabigatran with verapamil or diltiazem was found to be associated with an increased risk of bleeding in patients with normal kidney function, according to the findings of a recently published retrospective cohort study.
A recent review published in The Journal of Clinical Pharmacology summarizes the current literature evaluating the potential risks associated with concomitant use of cannabis and antiplatelet agents or anticoagulants.
To shed light on this complex subject, MPR interviewed Joshua D Brown, PharmD, PhD, Assistant Professor, Pharmaceutical Outcomes & Policy.
The patient in this case had been well-controlled on warfarin therapy for over 5 years following mitral valve replacement.
Aspirin does not appear to reduce the risk of nonarteritic ischemic optic neuropathy development in men, according to data presented at the 2019 American Academy of Ophthalmology Meeting in San Francisco, CA.
Results from a new real-world study evaluating rivaroxaban (Xarelto; Janssen), a factor Xa inhibitor, in morbidly obese patients were recently published in Thrombosis Research. The retrospective cohort study analyzed data from 2 US claims databases (Truven MarketScan Commercial Claims and Encounters database and MarketScan Medicare Supplemental database) to evaluate the clinical and health/economic outcomes of…
“The elevation in INR can be explained by the inhibition of CYP2C9 by cannabis use causing decreased metabolism of warfarin,” the authors explained.
A recent report highlights the importance of using rivaroxaban cautiously in morbidly obese.
Safety Alerts and Recalls
The Food and Drug Administration (FDA) is warning patients and caregivers not to use test strips from previous owners or ones not authorized for sale in the US.
Results from a real-world study evaluating rivaroxaban (Xarelto; Janssen) in newly diagnosed patients with nonvalvular atrial fibrillation (NVAF) were presented at the American College of Cardiology's (ACC) 68th Annual Scientific Session.